- Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections
- Demonstrated its Efficacy and Safety through previous Clinical Trials
- Company seeks global partners to co-develop toward Commercialization
SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ — iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and unmet medical needs, today announced the strategic initiative aimed at expanding the clinical applications of SAL200 and seeking a strategic partnership to target the prevention of surgical site infections (SSIs) by nasal MRSA decolonization.
Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most dangerous superbugs worldwide, with rising infection rates in both hospital and community settings. Even in sterile operating environments, MRSA-related SSIs frequently originate from the patient’s own nasal or skin, potentially leading to extended hospital stays, increased treatment costs, and in severe cases, serious systemic infections such as sepsis, osteomyelitis, or endocarditis.
High-risk surgical patients including those undergoing implant or cardiac surgeries, or those with compromised immune systems face significantly elevated risks of MRSA infections. Although mupirocin-based nasal ointments have been used as a standard of care product for the prevention of SSI, resistance rates are continuously increasing, leaving clinicians with few effective solution.
As an intravenous injection drug for infective endocarditis and bacteremia, SAL200 has already demonstrated a strong safety profile through Phase 1a/1b and Phase 2a clinical trials. Encouraged by recent feedback from key clinical experts, iNtRON is now pursuing an additional indication for SAL200 as a pre-operative MRSA nasal decolonization solution.
According to recent industry reports, the global nasal decolonization market which is closely related to SSI prevention was valued at USD 1.6 billion in 2024 and is projected to grow at a CAGR of 7.5%, driven by heightened hospital infection control regulations and growing concern over antimicrobial resistance.
With the strategic expansion of the clinical application of SAL200 for the promising market opportunity, iNtRON is seeking global partners to co-develop a new formulation, delivery route, and product type as a nasal or topical use, and to collaborate on preclinical and clinical studies aimed at commercialization.
“As SAL200 has demonstrated its strong efficacy and safety as an I.V. injection formulation in the previous clinical studies, we believe it can be developed into a nasal or topical use formulation through a much simplified clinical trial process” said YOON Kyung Won, CEO. “We believe SAL200 can fill a critical gap in MRSA nasal decolonization, an area in urgent need of a new solution. We aim to begin clinical development for this new indication in 2025 and are confident that our novel solution will significantly advance efforts to prevent MRSA-related SSIs. We are open to all types of partnerships including co-development and licensing, and welcome discussion with those who share our vision.“
About iNtRON Biotechnology, Inc.
iNtRON Biotechnology (www.iNtODEWORLD.com) is a clinical-stage biopharmaceutical company at the forefront of bacteriophage-derived technology and immune therapeutics. The company specializes in developing first-in-class and first-in-concept bio-drugs to combat infectious diseases and immune-related disorders. Since its foundation and subsequent IPO on KOSDAQ, iNtRON has focused on global R&BD collaborations and is committed to delivering innovative therapies that address urgent medical needs in infectious disease and immunotherapy.
Contact Us
YOON, Kyung Won (Kevin) / CEO, Vice President / kwyoon@intron.co.kr
SHIN, Tae Kyu (TK) / BD Team Leader / tkshin@intron.co.kr
www.intodeworld.com
it is iNtRON.
